Mansoori Behzad, Mohammadi Ali, Davudian Sadaf, Shirjang Solmaz, Baradaran Behzad
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Adv Pharm Bull. 2017 Sep;7(3):339-348. doi: 10.15171/apb.2017.041. Epub 2017 Sep 25.
Anticancer drugs resistance is a complex process that arises from altering in the drug targets. Advances in the DNA microarray, proteomics technology and the development of targeted therapies provide the new strategies to overcome the drug resistance. Although a design of the new chemotherapy agents is growing quickly, effective chemotherapy agent has not been discovered against the advanced stage of cancer (such as invasion and metastasis). The cancer cell resistance against the anticancer agents can be due to many factors such as the individual's genetic differences, especially in tumoral somatic cells. Also, the cancer drug resistance is acquired, the drug resistance can be occurred by different mechanisms, including multi-drug resistance, cell death inhibiting (apoptosis suppression), altering in the drug metabolism, epigenetic and drug targets, enhancing DNA repair and gene amplification. In this review, we outlined the mechanisms of cancer drug resistance and in following, the treatment failures by common chemotherapy agents in the different type of cancers.
抗癌药物耐药性是一个由药物靶点改变引起的复杂过程。DNA微阵列、蛋白质组学技术的进步以及靶向治疗的发展为克服耐药性提供了新策略。尽管新型化疗药物的设计发展迅速,但尚未发现针对癌症晚期(如侵袭和转移)的有效化疗药物。癌细胞对抗癌药物的耐药性可能归因于许多因素,如个体的基因差异,尤其是肿瘤体细胞中的差异。此外,癌症耐药性是后天获得的,耐药性可通过多种机制产生,包括多药耐药、细胞死亡抑制(凋亡抑制)、药物代谢改变、表观遗传和药物靶点改变、DNA修复增强以及基因扩增。在本综述中,我们概述了癌症耐药性的机制,随后阐述了不同类型癌症中常见化疗药物的治疗失败情况。